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Letters to the Editor 
IS MONITORING OF PLATELETS NECESSARY 
DURING CLOZAPINE THERAPY ? 
Sir, 
The availability of clozapine in India at 
prices relatively lower than those in the west has 
made this a feasible treatment option for many 
patients with schizophrenia or schizoaffective 
disorder whose illness had not responded to 
conventional treatment. However, it is still an 
expensive treatment, added to which are the 
costs of haematological monitoring. In order to 
minimise treatment costs, it is imperative to 
review the schedule for monitoring in the Indian 
context, to reflect the actual risk of 
agranulocytosis (Tharyan, 1998). 
Current recommendations do not require 
the routine monitoring of platelet counts but a 
report by Eranti & Chaturvedi (1998) 
documenting asymptomatic marked thrombocyte 
fluctuations, without similar leucocyte varietions 
or agranulocytosis, suggested the need for routine 
platelet monitoring. There is little evidence at 
' present to support such a recommendation. In 
addition, spurious results may be obtained with 
routine thrombocyte counts that may result in 
deserving patients being potentially denied 
effective therapy, as is illustrated by the following 
example. 
A 22-year-old single male was started 
on haloperidol in 1991 for a psychotic illness, 
which on follow up was diagnosed as 
schizoaffective disorder - bipolar type, fulfilling 
diagnostic criteria in DSM - IV (American 
Psychiatric Association, 1995). Lithium was 
added in 1996 after the emergence of manic 
symptoms and subsequently he has had a 
fluctuating course requiring continued 
haloperidol for persistent delusional beliefs and 
intermittent treatment with fluoxetine for 
depressive episodes. Haloperidol was replaced 
by risperidone 8 mg/day in mid 1997 and in early 
1998 carbamazepine was added to achieve 
better mood control. By mid 1998, he started 
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evidencing buccolingual involuntary movements 
and in view of his distressing mood fluctuations 
and persistent delusional beliefs, a decision was 
made to try mono-therapy with clozapine. 
Baseline white cell count was normal but 
platelet count was 83,000/cu mm. Since he 
evidenced no clinical features of 
thrombocytopaenia, a repeat platelet count was 
ordered. Simultaneously all psychotropic 
medication was tapered off and clozapine was 
initiated at 25 mg/day on 19/10/98. Platelet count 
on 24/10/98 was 1,10,000/cu mm on a clozapine 
dose of 75 mg/day. Clozapine was continued but 
as a matter of caution, platelet counts were 
ordered on 28/10/98. 
On 31/10/98 the patient was seen by 
another consultant who, on noting a platelet 
count of 82,000/cu mm with a total WBC count 
of 8,500/cu mm, stopped clozapine. A platelet 
count repeated on the same day was 86,000/cu 
mm, again with a normal total and differential 
white cell count and no symp.toms of 
thrombocytopaenia. 
At this point a consultation was sought 
with haematologists who advised that a manual 
count of the slide be performed on the last sample 
of blood given for platelet evaluation. This was 
reported to show 1,20,000 platelets/cu mm. 
According to the haematologists, the reason for 
the low platelet counts on previous occasions was 
probably erroneous readings produced by 
automated counts with the Coulter counter, which 
tends to read platelet aggregates as a single large 
platelet, thereby under-reporting the total number 
of platelets. A manual count revealed this error. 
Clozapine was restarted on the next day 
and subsequent platelet counts done manually 
have all been normal, albeit with marked 
variations in absolute number. The patient is 
currently fully functional on a clozapine dose of 
150 mg/day, employed, euthymic and free of 
delusional beliefs. Monitoring of platelet counts 
has been long discontinued 
Unless systematic evaluation re'veals 
symptomatic thrombocytopaenia or 
thrombocytosis, independent of agranulocytosis 
induced by clozapine, routine monitoring of 
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platelets appears unwarranted at present. 
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DEPRESSIVE DISORDER IN THE ELDERLY 
Sir, 
A consensus update conference on the 
diagnosis and treatment of late life depression was 
held in January, 1996 in USA and its proceedings 
have been summerized by Katz & Alexopolus 
(1996). 
The conclusions drawn are similar to the 
impression of a large majority of experienced 
mental health professionals in India viz. : 
(i) Depression among elderly persons often 
remains undiagnosed and untreated because'of 
a wrong common belief that it is a part of normal 
ageing. The expert panel concluded that nearly 
5 million American age 65 or older suffer from 
depressive symptoms and of these at least one 
million suffer from major depression (DSM-IIIR). 
A great majority of elderly persons who 
committed suicide (75%) had visited primary 
care physician within the preceeding one month 
but their symptoms were unrecognised. I also 
had a similar experience in that three elderly 
persons known to me who committed suicide 
had been to their family doctor within 3-4 weeks 
of the incident but their depressive symptoms 
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were not noticed. 
(ii) In elderly person a medical illness or 
hospitalisation for a surgical intervention is a 
frequent concomitant for a depressive episode and 
should be given treatment for depression also, 
(iii) Depression is more common in the elderly 
than in general population. The prevalence rate 
is 25% to 40% and is more often associated 
with low socio-economic status loss of spouse 
or a concomitant physical illness (Kaplan et 
al.,1994). 
(iv) The greatest number of suicides (25%) 
occurs in the elderly group although they are 
only 10% of the population (Kaplan et al.,1994). 
(v) Treatment: Age alone is no contraindication for 
ECT which should be used freely where otherwise 
indicated (Lebourtz, 1996). In older textbooks a 
condition called "Involutional Melancholia" was 
described in the elderly age group. It had a very 
good prognosis and ECT was particularly indicated 
in this condition. The oldest patient I gave ECT 
was an eighty six years old lady and at that time we 
had no facilities to give relaxants. It does not mean 
that senior citizens requiring ECT now should be 
denied these facilities. 
(vi) Tricyclic antidepressants- fluoxetine and 
sertraline have been found equally effective 
(Schneider, 1996). 
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